Cheshire Medical Center is offering treatments and preventative therapies for those who are eligible.
Some new medications have received emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat mild-to-moderate COVID-19. These therapies are for use in individuals at high risk of developing severe illness if infected with COVID-19. Most individuals with COVID-19 have mild illness and can recover at home without medical care. Read more from Dartmouth Hitchcock Medical Center and Clinics about common symptoms and recovering at home.
Cheshire Medical Center will provide Paxlovid (oral medication) and Bebtelovimab, an intravenous injection, for the treatment of COVID-19, on an outpatient basis for eligible patients. These treatments remain active against all known COVID-19 variants circulating in the region at this time.
The new oral antiviral therapies, Paxlovid and molnupiravir, are now being supplied to certain retail pharmacies in New Hampshire, and are available through a prescription from your primary care provider if you are COVID-19 positive, symptomatic, and considered high risk for complications from the disease.
Note: Paxlovid and monoclonal antibodies are endorsed for use for pregnant women by the Society for Maternal Medicine and by the American College of Obstetrics and Gynecology.
None of these treatments is an alternative to getting vaccinated and boosted or wearing a mask.
Paxlovid (nirmatrelivir/ritonavir) is an antiviral pill used to treat mild-to-moderate COVID-19 in patients ages 12 and older who have tested positive for COVID-19 and who are at an increased risk of severe illness or hospitalization. This medication requires a prescription and should be taken within 5 days after the start of symptoms.
Results of a clinical study showed an 88% decrease in the risk of hospitalization or death at 28 days as compared with a placebo. Laboratory studies also showed that Paxlovid was effective against the Omicron variant. Paxlovid is not meant to be used to prevent infection or to prevent illness after being exposed to COVID-19.
It is a new anti-SARS-CoV-2 monoclonal antibody that received emergency use authorization by the FDA on February 11, 2022. It retains neutralizing activity against all known COVID-19 variants that are currently circulating. There has been Phase 2 trial data demonstrating more rapid viral decay in patients with COVID-19 following receipt of Bebtelovimab, compared to placebo. While there are insufficient data on hospitalization and mortality outcomes in patients who have received Bebtelovimab, this agent has a mechanism of action similar to other anti-SARS-CoV-2 monoclonal antibodies that have demonstrated a reduction in hospitalization or death in high-risk patients in Phase 3 trials.
Molnupiravir is an antiviral pill used to treat mild-to-moderate COVID-19 in patients ages 18 and older who have tested positive for COVID-19 and who are at an increased risk of severe illness or hospitalization. Molnupiravir can only be prescribed in patients who are not able to receive Paxlovid due to drug interactions, certain chronic health conditions, or lack of availability. This medication requires a prescription and should be taken within 5 days from the start of symptoms.
Results of a clinical study showed a 31% decrease in the risk of hospitalization or death at 29 days as compared to placebo. Laboratory studies also showed that molnupiravir was effective against the Omicron variant. Molnupiravir is not meant to be used to prevent infection or to prevent illness after being exposed to COVID-19.
Molnupiravir is not authorized for use in patients under the age of 18. While pregnancy is not an absolute contraindication for use, fetal toxicity has been observed in animal models at significantly higher exposures than with human dosing, and risk of use in pregnancy may outweigh the benefit. Discussion with your health care provider on the risks and benefits of molnupiravir and the available alternatives in pregnancy is required before prescribing. If taking molnupiravir, women of child-bearing age should use a reliable method of contraception during treatment and for at least 4 days afterwards, while men of child-bearing age should use a barrier form of contraception during treatment and for at least 3 months after.
Getting your COVID-19 treatments at Cheshire
Currently, there are several steps involved in getting one of the above COVID-19 treatments. In order to be eligible to receive one of these medications, you need to test positive for COVID-19 and be at increased risk for severe illness or hospitalization. This is bound to change, so please keep checking this page for updated information.
Please contact your primary care provider to determine your best treatment option for COVID-19.
Please note that your insurance company may be billed for your monoclonal antibody treatment. If you have questions about your coverage, please contact your insurance company. Dartmouth Health provides financial assistance for those who are unable to pay for their medical care based on their individual financial situation.
Preventive therapies are used to prevent COVID-19 infections for those who are at high risk of getting severe disease if they are infected with COVID-19.
Dartmouth Health will be offering AstraZeneca’s Evusheld™ (tixagevimab and cilgavimab), a monoclonal antibody designed to provide additional immunity and prevent COVID-19 in individuals 12 years of age or older who are moderately to severely immunocompromised. Evusheld may also be used in individuals who are not able to receive the available COVID-19 vaccines due to a history of severe adverse reaction.
For more information, please contact your provider at Cheshire Medical Center.
Learn more about COVID-19 preventive measures.